A Non-interventional Two-arm Two-centre, Retrospective/Prospective Study to Compare the Effect of Alendronate 70mg Formulation (Tablet vs Effervescent Tablet) on Bone Turnover Markers and Patient Reported Outcomes
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Alendronic acid (Primary) ; Alendronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Labatec Pharma
- 01 Dec 2020 Planned End Date changed from 1 Aug 2019 to 1 Dec 2022.
- 01 Dec 2020 Planned primary completion date changed from 1 Aug 2019 to 31 Mar 2022.
- 01 Dec 2020 Status changed from not yet recruiting to recruiting.